CD4 and Patent ductus arteriosus: PDA patients were divided into two groups based on the median value obtained for either tumor-infiltrating Tregs (17.37% in CD4+ T cells) or tumor-infiltrating CD8+ T cells (28.69% in CD3+ T cells) (Table 2).